Premium
Inhaled aprotinin reduces viral load in mild‐to‐moderate inpatients with SARS‐CoV‐2 infection
Author(s) -
RedondoCalvo Francisco Javier,
Padín Juan Fernando,
MartínezAlarcón José,
MuñozRodríguez José Ramón,
SerranoOviedo Leticia,
LópezJuárez Pilar,
Porras Leal María Lourdes,
González Gasca Francisco Javier,
Rodríguez Martínez Marta,
Pérez Serrano Raúl,
Sánchez Cadena Abraham,
BejaranoRamírez Natalia,
Muñoz Hornero Constanza,
Villegas FernándezInfantes María Dolores,
Manrique Romo María Isabel,
GómezRomero Francisco Javier,
PérezOrtiz José Manuel
Publication year - 2022
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13850
Subject(s) - aprotinin , ritonavir , medicine , proteases , population , protease inhibitor (pharmacology) , intensive care medicine , immunology , virus , viral load , virology , biology , biochemistry , environmental health , antiretroviral therapy , enzyme